🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tom Powles OncoAlert In this setting we urgently need prospective biomarker trials to define the real impact no only for KIM 1, serum glicoproteins and others. Probably, future will be multiomic in RCC biomarkers?

Esta mañana arrancó en📍Madrid el #GUARDSymposium2025 Dr. Roberto Iacovelli 🇮🇹 analizando qué hacer tras progresión a TKI+IO en 1L. 📊 % de pacientes que recibieron 2L: KN-426 (Axi+Pembro): 58% CM9ER (Cabo+Nivo): 43% CLEAR (Lenva+Pembro): 51% OncoAlert

#GUARDSymposium2025 SBRT renal gana terreno en pacientes no candidatos a cirugía. Abrahams Ocanto 📌 Control local a 2 años: 97.8% 📌 Buen perfil de toxicidad 📌 Candidatos ideales: T1, M0, NO, eGFR ≥30 GUARD Consortium OncoAlert Uromigos

FGFR inhibition in FGFR3 altered UC doesn’t get the attention it deserves #GUARDSymposium2025 Its data platinum refractory UC is similar to EV. It’s used in late disease. Sadly there are no R3s 1st line or combo studies. The survey below shows enthusiasm post EVP OncoAlert

BCG pretreated NMIBC is moving fast in the USA with rapid FDA approvals from single arm trials. The drugs look active but ‘rapid’ study design creates uncertainty #GUARDSymposium2025 Uromigos Joshua Meeks OncoAlert Europe is going in a different direction, both can’t be right?

A propósito del #GUARDSymposium2025 🔍Repasamos los F3 en 1LmRCC 📌 Todos los combos con IO mejoran OS, PFS, ORR vs TKI solo. 📌Ipi/Nivo: HR OS consistente, rtas + duraderas. 📌IO/TKI: reducción tumoral, + ORR y PFS. 📊 Comparar es difícil: elige 1 y úsalo bien. OncoAlert

En #GUARDSymposium2025 ayer se destacó la necesidad de estudios prospectivos en bmk para CCR. 🔍 ¿Qué sabemos hasta ahora? Múltiples ensayos y combinaciones VEGF/IO: PD-L1 inconsistente, KIM1 prometedor. 👉🏻 El futuro serán firmas multi-ómicas, bmk circulantes... OncoAlert

En 🇺🇸 se avanza rápidamente en NMIBC post-BCG: FDA ha aprobado combinaciones en estudios sin brazo control. 🤔 Los fármacos son activos, el diseño acelerado deja dudas. Y 🇪🇺 va en otra dirección. ¿Qué camino será el adecuado? #GUARDSymposium2025 OncoAlert Uromigos

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. Brian Rini, MD OncoAlert

💭 ¿Qué tratamiento daríais a un paciente tras progresión a EVP (> 6 meses suspendido por tox, resuelta)? El paciente tiene alteración en FGFR3 y es HER2+ 👇🏼👇🏼

Escenario complejo y con opiniones divididas. #GUARDSymposium2025 🗒️ 2L ADC/Tx dirigidas (F3): 🔵EV (Nectin/MMAE): RR 41 %, mejora PFS/OS 🟢SG (TROP2/TOPO1): RR 24 %, negativo en OS 🔴Taxol-Ramu: RR 24 %, mejora PFS 🟣Erdafitinib (FGFR+): RR 45 %, mejora PFS/OS OncoAlert

LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Matt Galsky🇺🇸 How to select patients in whom we preserve the bladder without local treatment? Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente

🌟🚨 FGFR3-altered UC still overlooked! Despite solid data in platinum-refractory disease, FGFR inhibition lags behind in trials and attention. Important reminder by Tom Powles from #GUARDSymposium2025 👇 OncoAlert Enrique Grande Matt Galsky Andrea Necchi Daniel Castellano Javier Puente

In this episode Dr. Silke Gillessen joins the show to discuss highlights from the ASCO 2025 Annual Meeting with Brian and Tom. 🎙️ GU Oncology Now: buff.ly/fOkhcua 🍎 Apple Podcasts: buff.ly/nBn26Rm 🎧Spotify: buff.ly/knZCF5D

🇬🇷 🌍Great Greek GU program ASCO #Athensmeeting Petros Grivas Prostate cancer Nick James also on @Prof-Nick-James.bsky.social Atish Choudhury, MD PhD Bladder cancer & UTUC Stephanie Berg Dr. Jason Efstathiou Terry Friedlander Renal Cell carcrinoma Maite Bourlon Participation: Shilpa Gupta Karima Oualla, MD,MSc Ashish M. Kamat, MD, MBBS Congrats!!😍

I’m not “riding my bike” this year ….but still raising funds for the Pan-Mass Challenge Challenge ! Everyone can have an impact to cure cancer Dana-Farber Link: profile.pmc.org/TC0306

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…

The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour with America’s 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇮🇳 🇦🇺 🇪🇺 Uromigos Cup competition (details to follow). Sessions ranging from ADCs in MIBC to the changing shape of

Professor Christopher Booth of Queen’s University in Kingston, Ontario, Canada, joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemotherapy in colorectal cancer. We discuss

Listen to the first installment of our IMPACT series. Axel Bex joins us to discuss impactful clinical trials in RCC. We discuss CARMENA, SURTIME, consolidative approaches, neoadjuvant trials and touch on what has impacted his career trajectory. spotifycreators-web.app.link/e/JdPG3RiXZUb